Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life.
dc.contributor.author | Richards, M A | |
dc.contributor.author | Hopwood, Penelope | |
dc.contributor.author | Ramirez, A J | |
dc.contributor.author | Twelves, C J | |
dc.contributor.author | Ferguson, Janice E | |
dc.contributor.author | Gregory, W M | |
dc.contributor.author | Swindell, Ric | |
dc.contributor.author | Scrivener, W | |
dc.contributor.author | Miller, J | |
dc.contributor.author | Howell, Anthony | |
dc.date.accessioned | 2010-08-16T14:04:37Z | |
dc.date.available | 2010-08-16T14:04:37Z | |
dc.date.issued | 1992 | |
dc.identifier.citation | Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. 1992, 28A (6-7):1023-8 Eur J Cancer | en |
dc.identifier.issn | 0959-8049 | |
dc.identifier.pmid | 1627368 | |
dc.identifier.doi | 10.1016/0959-8049(92)90447-A | |
dc.identifier.uri | http://hdl.handle.net/10541/109628 | |
dc.description.abstract | The influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups. | |
dc.language.iso | en | en |
dc.subject | Breast Cancer | en |
dc.subject | Cancer Metastasis | en |
dc.subject | Cancer Recurrence | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Doxorubicin | |
dc.subject.mesh | Drug Administration Schedule | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Metastasis | |
dc.subject.mesh | Neoplasm Recurrence, Local | |
dc.subject.mesh | Quality of Life | |
dc.subject.mesh | Survival Analysis | |
dc.subject.mesh | Treatment Outcome | |
dc.title | Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. | en |
dc.type | Article | en |
dc.contributor.department | Imperial Cancer Research Fund, Guy's Hospital, London, U.K. | en |
dc.identifier.journal | European Journal of Cancer | en |
html.description.abstract | The influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups. |